PD suppresses the lung metastasis of breast cancer by downregulating PD-L1 expression and enhances the anticancer effects of sorafenib in AKT-positive and PTEN-negative prostate cancer cells through the ubiquitination of p-Akt 119, 120. Here, AKT1 is linked to prostate carcinoma.